Peptide News Digest

#Dementia

2 stories

Research · View digest

GLP-1 Drug Users Had About Half the Rate of Dementia Diagnoses After a Minor Stroke in a TriNetX Records Study

Researchers led from West Virginia University matched 1,425 adults with minor ischemic stroke who took a GLP-1 drug before or within three months of the stroke with 1,425 who did not; 92.7% had diabetes. Over five years, 3.4% vs. 7.0% were diagnosed with dementia (hazard ratio 0.52, 95% CI 0.37 to 0.74), and 4.4% vs. 8.8% died. The Journal of Neurology authors say prospective trials are needed to confirm causality.

Research · View digest

AAN 2026 Living Review: GLP-1 Agonists Cut Dementia Incidence 20-35% Across 2M+ Diabetics

A living systematic review presented at the American Academy of Neurology 2026 Annual Meeting integrating Phase 2/3 trials and real-world data from 2+ million individuals with diabetes found GLP-1 receptor agonist use was associated with a 20-35% lower incidence of dementia versus DPP-4 or SGLT2 inhibitors. Effect was strongest for semaglutide, despite the EVOKE Phase 3 Alzheimer's trial missing its cognitive endpoint.